细胞程序性死亡蛋白1配体1(PDL1)重组蛋白
Recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1)
CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1
- 编号RPA788Hu02
- 物种Homo sapiens (Human,人) 相同的名称,不同的物种。
- 来源原核表达
- 宿主E.coli
- 内毒素水平<1.0EU/µg(LAL法测定)
- 亚细胞定位细胞膜, 内体
- 预测分子量28.9kDa
- 实际分子量33kDa(差异分析请参阅说明书)
- 片段与标签Phe19~Arg238 with N-terminal His Tag
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 95%
- 等电点6.0
-
应用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,请参见活性蛋白。 - 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 1032 ¥ 2580 ¥ 5160 ¥ 15480 ¥ 38700
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
增值服务
相关产品
编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) |
RPA788Hu02 | 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA788Hu01 | 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA788Hu61 | 细胞程序性死亡蛋白1配体1(PDL1)活性蛋白 | Cell culture; Activity Assays. |
EPA788Hu61 | 细胞程序性死亡蛋白1配体1(PDL1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA788Hu01 | 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 | WB,ICC/IF |
FAA788Hu01 | 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 | Flow cytometry. |
FAA788Hu41 | 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(藻红素标记) | Flow cytometry. |
FAA788Hu51 | 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(别藻蓝蛋白标记) | Flow cytometry. |
FAA788Hu81 | 抗细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体(异硫氰酸荧光素标记) | Flow cytometry. |
MAA788Hu28 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
MAA788Hu22 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
RAA788Hu22 | 细胞程序性死亡蛋白1配体1(PDL1)重组抗体 | WB; IF; ICC; IHC; IP; FCM. |
MAA788Hu21 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
MAA788Hu23 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
MAA788Hu24 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
MAA788Hu25 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
MAA788Hu27 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
MAA788Hu29 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
MAA788Hu26 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体 | WB; IHC; ICC; IP. |
RAA788Hu21 | 细胞程序性死亡蛋白1配体1(PDL1)重组抗体 | WB; IF; ICC; IHC; IP; FCM. |
LAA788Hu72 | 细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体(生物素标记) | WB; IHC; ICC. |
FAA788Hu82 | 抗细胞程序性死亡蛋白1配体1(PDL1)单克隆抗体(异硫氰酸荧光素标记) | Flow cytometry. |
WEA788Hu | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法,宽范围) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SEA788Hu | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCA788Hu | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(化学发光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMA788Hu | 细胞程序性死亡蛋白1配体1(PDL1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
PSA788Hu01 | 细胞程序性死亡蛋白1配体1(PDL1)抗体对 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
KSA788Hu01 | 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒DIY材料(酶联免疫吸附试验法) | Main materials for "Do It (ELISA Kit) Yourself". |
参考文献
杂志 | 参考文献 |
Chinese Journal of Cancer | Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742] |
Leukemia.? | High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592] |
Diabetes?Metab Res Rev. | PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853] |
Lancet Haematol | Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046] |
Eur J Cancer. | High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170] |
Journal of Cancer Research and Clinical Oncology | Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007] |
Journal of Hematology & Oncology | PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703] |
Lung Cancer. | High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990] |
Oncotarget | Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy. [pubmed:27780932] |
Oncotarget | High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients. [pubmed:27105512] |
Oncotarget. | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569] |
Cancer Immunol Immunother. | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165] |
Leukemia | Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a] |
Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525] |
Allergology International | Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656] |
Medicine | Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514] |
American Journal of Respiratory and Critical Care Medicine | Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164] |
Clinical Lung Cancer | Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759] |
Journal of Rheumatology | Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471] |
Translational Oncology | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935] |
Immunology Letters | Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals [Pubmed: 30236481] |
Journal of Cancer Research and Clinical Oncology | Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma [Pubmed: 30267213] |
Annals of Surgical Oncology | Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between … [Pubmed: 30565045] |
American Journal of Reproductive Immunology | Identification of programmed cell death 1 and its ligand in the testicular tissue of mice [Pubmed: 30578744] |
PLoS One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated … [Pubmed: 30807610] |
Endocrine Connections | Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer [Pubmed: 31252406] |
Scientific Reports | Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer [Pubmed: 31366979] |
Critical Reviews in Oncology / Hematology | The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer [Pubmed: 31675543] |
PLoS One | Clinical implications of APOBEC3A and 3B expression in patients with breast cancer [Pubmed: 32176735] |
Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study [Pubmed: 32085544] |
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma [Pubmed: 32054467] | |
LIVER INTERNATIONAL | The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer [Pubmed: 32780918] |
CANCER IMMUNOLOGY IMMUNOTHERAPY | Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients [Pubmed: 32577816] |
Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure [Pubmed: 32443313] | |
Cancer Immunol Immunother | The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte [33688997] |
Acta Biochim Biophys Sin | Prognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management [34180502] |
EMBO J | Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology [34825707] |
Mol Pharm | A Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors [34910492] |
Mol Hum Reprod | Macrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis [Pubmed:35404426] |
Journal of Nanobiotechnology | Microbial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape [Pubmed:35705974] |
Medicina | Assessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A … [Pubmed:35208526] |
留言咨询